Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in October:

Tuesday, October 10, 2017Chardan Gene Therapy ConferenceWho: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences & eXtelliaLocation: New York, New YorkPresentation Time: 2:45 pm EDT

Thursday, October 12, 2017Jefferies Gene Therapy and Editing SummitWho: Nessan Bermingham, Ph.D., President, Chief Executive Officer and FounderLocation: New York, New YorkPresentation Time: 1:40 pm EDT

A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for 14 days following each conference.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Intellia Contacts:

Media Contact:                                                           Jennifer Mound Smoter                                              Senior Vice President, External Affairs                      & Communications                                                     +1 857-706-1071                                                        [email protected]

Investor Contact: Lindsey TrickettVice President, Investor Relations+1 857-285-6211[email protected]

Source: Intellia Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy
• Chardan Assumes Rocket Pharmaceuticals (RCKT) at Buy
• Orca Security Is Now Native in Japanese for Japan’s Enterprises and Partners